Edition:
United States

Biostage Inc (HART.OQ)

HART.OQ on NASDAQ Stock Exchange Capital Market

1.80USD
31 Mar 2016
Change (% chg)

-- (--)
Prev Close
$1.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
17,234
52-wk High
$3.46
52-wk Low
$0.53

HART.OQ

Chart for HART.OQ

About

Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient's own cells. It is developing... (more)

Overall

Beta: --
Market Cap(Mil.): $18.48
Shares Outstanding(Mil.): 17.11
Dividend: --
Yield (%): --

Financials

  HART.OQ Industry Sector
P/E (TTM): -- 37.20 36.83
EPS (TTM): -0.71 -- --
ROI: -104.63 12.50 13.93
ROE: -131.18 14.81 14.84

BRIEF-Biostage posts Q2 loss per share $0.17

* Biostage reports 2016 second quarter financial results and provides business update outlining key near-term milestones

Aug 11 2016

BRIEF-Biostage says files for stock shelf of up to $20 million - SEC filings

* Says files for stock shelf of up to $20 million - SEC filings Source text for Eikon: Further company coverage:

Aug 08 2016

BRIEF-Biostage files for FDA orphan drug designation for cellspan esophageal implant

* Biostage files for FDA orphan drug designation for cellspan esophageal implant Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 29 2016

BRIEF-Biostage CEO provides mid-year update to shareholders

* Now have capital to get through a number of milestones in 2016 including filing of IND; expect to move into human clinical trials in 2017

Jun 21 2016

BRIEF-Empery Asset Management reports 5.53 pct stake in Biostage

* Empery Asset Management, Lp reports 5.53% stake in Biostage as of May 15, 2016 - SEC filing Source text for Eikon:

May 20 2016

BRIEF-Biostage Director Thomas Robinson reports open market purchase

* Director Thomas Robinson reports open market purchase of 18,000 shares of co's common stock on May 19 at average price of $1.35 each - sec filing Source text - (http://1.usa.gov/1NBLhHT) Further company coverage:

May 20 2016

BRIEF-Biostage regenerates esophagus in pre-clinical work with Mayo Clinic

* Says biostage currently expects to complete its ind filing by year-end 2016

May 12 2016

BRIEF-Biostage Q1 loss per share $0.18

* Bioengineered organ implant developer Biostage reports q1 2016 results and hosts research update call today at 9:00 am et

May 12 2016

Earnings vs. Estimates